PlantPharm Biomed, a leader in plant-derived biomanufacturing, is on the cusp of introducing one of the first Plant-Made Pharmaceuticals (PMPs) with the release of an oral Hepatitis B vaccine proven to work in human subjects in a double-blind, placebo controlled Phase I clinical trial. The company is currently seeking FDA approval of the product, with other Plant-Made Pharmaceuticals products to follow.
Plant-Made Pharmaceuticals offer a faster, lower cost, more efficient method of producing pharmaceuticals, however, the industry has been struggling for years to find a method of production that is safe and effective. To achieve success, pharmaceutical proteins in plants must be grown in a zero-tolerance, 100% containment method for the public safety, with no potential to co-mingle with the food or seed supply. PlantPharm Biomed developed a proprietary, closed-environment growing system that has been perfected in cooperation with NASA. This biomanufacturing technology includes 30 patents and registrations worldwide, and the controlled environment production of fast growth, pathogen-free seed potatoes has been perfected by the company for more than a decade. PlantPharm is pleased to announce that the technology is now ready for use in biomanufacturing Plant-Made Pharmaceuticals.
Read complete press release here
No comments:
Post a Comment